Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Cathy Kelly
Agency hears from experts on whether PBMs and group purchasing organizations operate under misaligned incentives.
The Pharmaceutical Research and Manufacturers of America says the US Centers for Medicare and Medicaid Services should not itself initiate experiments with value-based payment approaches. Any demonstrations led by agency's CMMI should focus on "holistic" approaches to health costs.
Medicare Part D proposed rule would lower cost sharing for biosimilars to the level of generics for some beneficiaries, allow immediate generic substitution for plans.
CMS outlines possible approach to point-of-sale rebates in Medicare Part D, recognizing that using rebates to lower cost sharing for 'many' would increase premiums for all.
Concerns with promoting competition and reducing consumers' 'pain in the pocketbook' are key tenets of the Trump Administration's approach to lowering prescription drug pricing, Grogan says.
Insurance practices are a big driver of drug pricing problems, according to Azar, a former Lilly exec who spent six years at HHS under George W. Bush, providing him valuable experience in department operations.